Shareholder update

15th October 2025, Sydney, Australia

Clinical-stage Australian life sciences company **Filamon Limited** ("**Filamon**" or "**the Company**") is pleased to provide shareholders with an update on compelling pre-clinical data recently produced by its BETA-TT8 ophthalmology program, targeting wet age-related macular degeneration ("wet AMD").

Wet AMD occurs when abnormal blood vessels grow under the retina and leak fluid or blood into the macula, the part of the eye responsible for central vision.[1] AMD is **the** major cause of loss of vision in older people, affecting an estimated 200 million people globally with approximately 15% of patients progressing to wet AMD.[2]

Filamon has recently received data from its BETA-TT8 Mouse model efficacy via oral dosage study, which was led by Filamon's Dr. Quach Truong and undertaken at contracted clinical research organization ("CRO"), PharmaLegacy, San Diego, USA. The study was financed by Filamon, pursuant to a Commonwealth Cooperative Research Centres Projects (CRC-P) grant.

The study demonstrated a dose-response effect for BETA-TT8 as well as therapeutic efficacy in a recognized induced animal model of wet age-related macular degeneration in both dosage regimens, with outcomes comparable to those of the current standard of care model, injected Elyea (Aflibercept), for the higher dose BETA-TT8 regimen - as demonstrated in the graph below:



$^{**}p < 0.01$, $^{***}p < 0.001$: G2 - G4 vs G1 (Kruskal-Wallis test/Dunn's) [3]

[1] Macular Society, UK
[2] Filamon, Corporate Presentation October 2025
[3] Filamon Limited, October 2025

The Company will now consider the future clinical and pre-clinical pathway for BETA-TT8, orally administered. As shareholders will be aware, Filamon is currently awaiting data from it's pre-clinical efficacy trial for BETA-TT8 administered via its proprietary eye-dropper formulation.

The Company is confident that a potentially valuable clinical pathway now exists for BETA-TT8 via either administration method. It expects to form an external expert committee of clinician ophthalmologists over the next month.

Filamon is also pleased to advise that the Company's Dr. Quach Truong was a guest presenter at the 16th Australian Peptide Conference, held recently (12th to 17th October) in Launceston, Tasmania.

Dr. Truong presented in person Filamon's clinical-stage asset *Kesonotide*, subject of the recently launched ADVICE trial (Sydney, Australia) which is in patient recruitment stage. The Company also delivered a poster presentation regarding its pre-clinical LYTAPs class of drugs.

Finally, Filamon's Chief Executive Officer and Managing Director, Dr. Graham Kelly, will be presenting the recent BETA-TT8 in Ophthalmology data at the AusBiotech (2025) conference in Melbourne, Victoria, on Tuesday the 21st of October.

With the Company presently closing its pre-IPO capital raising round and commencing preparations for Initial Public Offering (IPO) in H1 of 2026, ongoing clinical and pre-clinical developments will be less frequently announced as the team, along with its mandated IPO Lead Manager (Blue Ocean Equities Limited) undertake prospectus preparation.

The Company expects to provide a comprehensive update to shareholders either in late 2025 or early 2026, contemporaneous with finalization of its pathfinder prospectus document.

Release approved by the Board of Filamon Limited

Investor enquiries/pre-registration/expressions of interest (IPO):

Dr. Graham Kelly

CEO

corporate@filamon.com

www.filamon.com